These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31322098)

  • 21. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial.
    Katzberg HD; Barnett C; Merkies IS; Bril V
    Muscle Nerve; 2014 May; 49(5):661-5. PubMed ID: 24810970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myasthenia gravis].
    Fleury MC; Tranchant C
    Rev Prat; 2008 Dec; 58(20):2217-24. PubMed ID: 19209651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A treatment algorithm for autoimmune myasthenia gravis in childhood.
    Andrews PI
    Ann N Y Acad Sci; 1998 May; 841():789-802. PubMed ID: 9668332
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.
    Pasnoor M; Wolfe GI; Nations S; Trivedi J; Barohn RJ; Herbelin L; McVey A; Dimachkie M; Kissel J; Walsh R; Amato A; Mozaffar T; Hungs M; Chui L; Goldstein J; Novella S; Burns T; Phillips L; Claussen G; Young A; Bertorini T; Oh S
    Muscle Nerve; 2010 Mar; 41(3):370-4. PubMed ID: 19882635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myasthenia gravis: how to treat?
    Tireli H; Karlikaya G; Tutkavul K; Akpinar A; Okay T
    Acta Myol; 2004 Dec; 23(3):140-5. PubMed ID: 15938570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
    Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
    Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous immune globulin in myasthenia gravis.
    Gajdos P
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):49-51. PubMed ID: 8033435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
    Allen JA; Scala S; Jones HR
    Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency and clinical features of treatment-refractory myasthenia gravis.
    Rath J; Brunner I; Tomschik M; Zulehner G; Hilger E; Krenn M; Paul A; Cetin H; Zimprich F
    J Neurol; 2020 Apr; 267(4):1004-1011. PubMed ID: 31828474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic plasma exchange in a patient of myasthenic crisis, refractory to intravenous immunoglobulin and immunosuppressive therapy.
    Prakash S; Hans R; Sharma RR; Lal V; Marwaha N
    Neurol India; 2017; 65(6):1409-1412. PubMed ID: 29133726
    [No Abstract]   [Full Text] [Related]  

  • 32. Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies.
    Europa TA; Nel M; Heckmann JM
    Muscle Nerve; 2018 Oct; 58(4):542-549. PubMed ID: 29790193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients.
    Dau PC
    Ann N Y Acad Sci; 1981; 377():700-8. PubMed ID: 6951494
    [No Abstract]   [Full Text] [Related]  

  • 34. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
    Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis.
    Liew WK; Powell CA; Sloan SR; Shamberger RC; Weldon CB; Darras BT; Kang PB
    JAMA Neurol; 2014 May; 71(5):575-80. PubMed ID: 24590389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immune system, Part 2: Myasthenia gravis.
    Stephens A
    Nurs Times; 1997 Nov 12-18; 93(46):56-9. PubMed ID: 9418490
    [No Abstract]   [Full Text] [Related]  

  • 37. Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
    Barnett C; Bril V; Kapral M; Kulkarni AV; Davis AM
    Neurology; 2017 Dec; 89(23):2357-2364. PubMed ID: 29101274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
    Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
    J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.
    Cutter G; Xin H; Aban I; Burns TM; Allman PH; Farzaneh-Far R; Duda PW; Kaminski HJ
    Muscle Nerve; 2019 Dec; 60(6):707-715. PubMed ID: 31487038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of plasma exchange therapy in patients with myasthenia gravis.
    Ebadi H; Barth D; Bril V
    Muscle Nerve; 2013 Apr; 47(4):510-4. PubMed ID: 23322564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.